CoChat
Sign Up
Cited by 40Multiple Myeloma Research and TreatmentsMicroRNA in disease regulationChronic Lymphocytic Leukemia Research

The DOI matches its Crossref record.

Downregulation of microRNA‑25‑3p inhibits the proliferation and promotes the apoptosis of multiple myeloma cells via targeting the PTEN/PI3K/AKT signaling pathway

Open access
Zi, Youmei, Zhang, Yingzi, Wu, Yanwei, Zhang, Lina, Yang, Ru, Huang, Yan·2020·International Journal of Molecular Medicine
DOI 10.3892/ijmm.2020.4841PMC PMC7834966
Open this paper in CoChat — free accountOpen PDF

Abstract

Numerous studies have confirmed that microRNAs (miRNAs or miRs) have important roles in cancer biogenesis and development including multiple myeloma (MM). MicroRNA‑25‑3p (miR‑25‑3p) has been proven to promote cancer progression, whereas its functions in MM has not yet been reported, at least to the best of our knowledge. Therefore, the present study aimed to investigate the function of miR‑25‑3p in MM and to identify the potential underlying mechanistic pathway. Herein, it was found that miR‑25‑3p expression was significantly increased in MM tissues and cell lines. The upregulation of miR‑25‑3p was closely associated with anemia, renal function impairment international staging system (ISS) staging and Durie‑Salmon (D‑S) staging. A high level of miR‑25‑3p was predictive of a poor prognosis of patients with MM. In vitro, the knockdown of miR‑25‑3p suppressed the proliferation and promoted the apoptosis of RPMI‑8226 and U266 cells, while the overexpression of miR‑25‑3p exerted opposite effects. In addition, phosphatase and tensin homolog deleted on chromosome 10 (PTEN), a well‑known tumor suppressor, was confirmed as a target of miR‑25‑3p in MM cells. Moreover, it was found that the PTEN expression levels were decreased, and inversely correlated with miR‑25‑3p expression levels in MM tissues. Further analyses revealed that the overexpression of PTEN exerted effects similar to those of miR‑25‑3p knockdown, whereas the knockdown of PTEN partially abolished the effects of miR‑25‑3p inhibitor on MM cells. Accompanied by PTEN induction, miR‑25‑3p promoted PI3K/AKT signaling pathway activation in MM cells. Collectively, these findings demonstrate critical roles for miR‑25‑3p in the pathogenesis of MM, and suggest that miR‑25‑3p may serve as a novel prognostic biomarker and therapeutic target of MM.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3892/ijmm.2020.4841

Cites

Statistics

Figures

Figure 1 miR-25-3p expression is significantly upregulated in MM tissues and MM cell lines. (A) Expression of miR-25-3p was detected in 50 bone marrow tissue samples from MM patients and 10 normal bone marrow tissue samples from healthy donors by RT-qPCR. (B) Expression of miR-25-3p in MM cell lines was determined by RT-qPCR. nPCs cells were used as control cells. Data are presented as the means ± SD of 3 independent experiments. **P<0.01 vs. nPCs. (C) Prognostic value of miR-25-3p for MM patients assessed by Kaplan-Meier analysis. MM, multiple myeloma; nPCs, normal plasma cells.
Figure 1 miR-25-3p expression is significantly upregulated in MM tissues and MM cell lines. (A) Expression of miR-25-3p was detected in 50 bone marrow tissue samples from MM patients and 10 normal bone marrow tissue samples from healthy donors by RT-qPCR. (B) Expression of miR-25-3p in MM cell lines was determined by RT-qPCR. nPCs cells were used as control cells. Data are presented as the means ± SD of 3 independent experiments. **P<0.01 vs. nPCs. (C) Prognostic value of miR-25-3p for MM patients assessed by Kaplan-Meier analysis. MM, multiple myeloma; nPCs, normal plasma cells.CC BY-NC-ND · PubMed Central
Figure 2 Knockdown of miR-25-3p suppresses cell proliferation and induces cell apoptosis. RPMI-8226 and U266 cells were transfected with the miR-25-3p inhibitor or miR-25-3p mimics for 48 h, and the cells were then used for analysis. (A) Transfection efficiency was assessed by RT-qPCR. (B and C) Cell proliferation was measured by CCK-8 assay at the indicated time points. (D) Cell apoptosis was measured by flow cytometry. Data are presented as the means ± SD of 3 independent experiments. *P<0.05, **P<0.01 vs. inhibitor NC group; ##P<0.01 vs. mimics NC group.
Figure 2 Knockdown of miR-25-3p suppresses cell proliferation and induces cell apoptosis. RPMI-8226 and U266 cells were transfected with the miR-25-3p inhibitor or miR-25-3p mimics for 48 h, and the cells were then used for analysis. (A) Transfection efficiency was assessed by RT-qPCR. (B and C) Cell proliferation was measured by CCK-8 assay at the indicated time points. (D) Cell apoptosis was measured by flow cytometry. Data are presented as the means ± SD of 3 independent experiments. *P<0.05, **P<0.01 vs. inhibitor NC group; ##P<0.01 vs. mimics NC group.CC BY-NC-ND · PubMed Central
Figure 3 Overexpression of miR-25-3p promotes cell proliferation and inhibits cell apoptosis. RPMI-8226 and U266 cells were transfected with the miR-25-3p mimics or mimics NC for 48 h, and then cells were used for analysis. (A and B) Cell proliferation was measured by CCK-8 assay at the indicated time points. (C) Expression of PCNA protein was measured by western blot analysis. (D) Cell apoptosis was measured by flow cytometry. Data are presented as the means ± SD of 3 independent experiments. *P<0.05, **P<0.01 vs. inhibitor NC group.
Figure 3 Overexpression of miR-25-3p promotes cell proliferation and inhibits cell apoptosis. RPMI-8226 and U266 cells were transfected with the miR-25-3p mimics or mimics NC for 48 h, and then cells were used for analysis. (A and B) Cell proliferation was measured by CCK-8 assay at the indicated time points. (C) Expression of PCNA protein was measured by western blot analysis. (D) Cell apoptosis was measured by flow cytometry. Data are presented as the means ± SD of 3 independent experiments. *P<0.05, **P<0.01 vs. inhibitor NC group.CC BY-NC-ND · PubMed Central
Figure 4 PTEN is a direct target of miR-25-3p. (A) Schematic of the PTEN1 3′UTR containing the miR-25-3p binding sites. (B) Luciferase assay of 293T cells co-transfected with Firefly luciferase constructs containing the PTEN wt or mut 3′UTRs and miR-25-3p mimics, mimics NC, miR-25-3p inhibitor or inhibitor NC, as indicated (n=3). Data are presented as the means ± SD of 3 independent experiments. (C and D) RPMI-8226 and U266 cells were transfected with miR-25-3p mimics, mimics NC, miR-25-3p inhibitor or inhibitor NC for 48 h, and the expression levels of PTEN mRNA and protein were determined by RT-qPCR and western blot analysis, respectively. Data are presented as the means ± SD of 3 independent experiments. **P<0.01 vs. mimics NC; ##P<0.01 vs. inhibitor NC. (E) Expression of miR-25-3p in MM cell lines was determined by RT-qPCR. nPCs cells were used as control cells. Data are presented as the means ± SD of 3 independent experiments. **P<0.01 vs. nPCs group. (F) PTEN expression was measured by RT-qPCR in 50 bone marrow tissue samples from MM patients and 10 normal bone marrow tissue samples from healthy donors. P<0.01 vs. healthy donor group. (G) Pearson's correlation analysis was used to analyze the correlation between the expression of PTEN and the expression of miR-25-3p expression in multiple myeloma tissues (r=−0.9118, P<0.01).
Figure 4 PTEN is a direct target of miR-25-3p. (A) Schematic of the PTEN1 3′UTR containing the miR-25-3p binding sites. (B) Luciferase assay of 293T cells co-transfected with Firefly luciferase constructs containing the PTEN wt or mut 3′UTRs and miR-25-3p mimics, mimics NC, miR-25-3p inhibitor or inhibitor NC, as indicated (n=3). Data are presented as the means ± SD of 3 independent experiments. (C and D) RPMI-8226 and U266 cells were transfected with miR-25-3p mimics, mimics NC, miR-25-3p inhibitor or inhibitor NC for 48 h, and the expression levels of PTEN mRNA and protein were determined by RT-qPCR and western blot analysis, respectively. Data are presented as the means ± SD of 3 independent experiments. **P<0.01 vs. mimics NC; ##P<0.01 vs. inhibitor NC. (E) Expression of miR-25-3p in MM cell lines was determined by RT-qPCR. nPCs cells were used as control cells. Data are presented as the means ± SD of 3 independent experiments. **P<0.01 vs. nPCs group. (F) PTEN expression was measured by RT-qPCR in 50 bone marrow tissue samples from MM patients and 10 normal bone marrow tissue samples from healthy donors. P<0.01 vs. healthy donor group. (G) Pearson's correlation analysis was used to analyze the correlation between the expression of PTEN and the expression of miR-25-3p expression in multiple myeloma tissues (r=−0.9118, P<0.01).CC BY-NC-ND · PubMed Central
Figure 5 Overexpression of PTEN inhibits the proliferation and promotes the apoptosis of MM cells. RPMI-8226 and U266 cells were transfected with pcDNA-PTEN or pcDNA-vector for 48 h, and the cells were then used for analysis. (A) Transfection efficiency was assessed by western blot analysis. (B and C) Cell proliferation was measured by CCK-8 assay at the indicated time points. (D) Cell apoptosis was measured by flow cytometry. Data are presented as the means ± SD of 3 independent experiments. *P<0.05, **P<0.01 vs. pcDNA-vector group.
Figure 5 Overexpression of PTEN inhibits the proliferation and promotes the apoptosis of MM cells. RPMI-8226 and U266 cells were transfected with pcDNA-PTEN or pcDNA-vector for 48 h, and the cells were then used for analysis. (A) Transfection efficiency was assessed by western blot analysis. (B and C) Cell proliferation was measured by CCK-8 assay at the indicated time points. (D) Cell apoptosis was measured by flow cytometry. Data are presented as the means ± SD of 3 independent experiments. *P<0.05, **P<0.01 vs. pcDNA-vector group.CC BY-NC-ND · PubMed Central
Figure 6 Knockdown of PTEN markedly reverses the effects of miR-25-3p inhibition on the proliferation and apoptosis of MM cells. (A) Transfection efficiency was assessed by western blot analysis following si-PTEN transfection in RPMI-8226 and U266 cells. RPMI-8226 and U266 cells were co-transfected with the si-PTEN and miR-25-3p inhibitor for 48 h, and the cells were then used for analysis. (B and C) Cell proliferation was measured by CCK-8 assay at the indicated time points. (D) Cell apoptosis was measured by flow cytometry. Data are represented as the means ± SD of 3 independent experiments. *P<0.05, **P<0.01 vs. inhibitor NC group; ##P<0.01 vs. miR-25-3p inhibitor.
Figure 6 Knockdown of PTEN markedly reverses the effects of miR-25-3p inhibition on the proliferation and apoptosis of MM cells. (A) Transfection efficiency was assessed by western blot analysis following si-PTEN transfection in RPMI-8226 and U266 cells. RPMI-8226 and U266 cells were co-transfected with the si-PTEN and miR-25-3p inhibitor for 48 h, and the cells were then used for analysis. (B and C) Cell proliferation was measured by CCK-8 assay at the indicated time points. (D) Cell apoptosis was measured by flow cytometry. Data are represented as the means ± SD of 3 independent experiments. *P<0.05, **P<0.01 vs. inhibitor NC group; ##P<0.01 vs. miR-25-3p inhibitor.CC BY-NC-ND · PubMed Central
Figure 7 Knockdown of miR-25-3p suppresses the activation of the PTEN/PI3K/AKT pathway. RPMI-8226 and U266 cells were co-transfected with the si-PTEN and miR-25-3p inhibitor for 48 h, and the cells were then used for analysis. (A) The levels of PTEN, p-AKT and p-mTOR were measured by western blot analysis. (B) The bands were semi-quantitatively analyzed using ImageJ software. β-actin protein was used as the inner control of PTEN; the results of phosphorylated proteins were calculated as the ratio of phosphorylated to total protein. Data are presented as the means ± SD of 3 independent experiments. *P<0.05, **P<0.01 vs. inhibitor NC group; ##P<0.01 vs. miR-25-3p inhibitor.
Figure 7 Knockdown of miR-25-3p suppresses the activation of the PTEN/PI3K/AKT pathway. RPMI-8226 and U266 cells were co-transfected with the si-PTEN and miR-25-3p inhibitor for 48 h, and the cells were then used for analysis. (A) The levels of PTEN, p-AKT and p-mTOR were measured by western blot analysis. (B) The bands were semi-quantitatively analyzed using ImageJ software. β-actin protein was used as the inner control of PTEN; the results of phosphorylated proteins were calculated as the ratio of phosphorylated to total protein. Data are presented as the means ± SD of 3 independent experiments. *P<0.05, **P<0.01 vs. inhibitor NC group; ##P<0.01 vs. miR-25-3p inhibitor.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 42

  1. [1]Terpos E Ntanasis-Stathopoulos I Gavriatopoulou M Dimopoulos MA Pathogenesis of bone disease in multiple myeloma: From bench to bedside Blood Cancer J 8 7 2018 10.1038/s41408-017-0037-4 29330358 PMC5802524 · DOI · Paper page
  2. [2]Nahi H Våtsveen TK Lund J Heeg BM Preiss B Alici E Møller MB Wader KF Møller HE Grøseth LA Proteasome inhibitors and IMiDs can overcome some high-risk cytogenetics in multiple myeloma but not gain 1q21 Eur J Haematol 96 46 54 2016 10.1111/ejh.12546 25779478 · DOI
  3. [3]Harding T Baughn L Kumar S Van Ness B The future of myeloma precision medicine: Integrating the compendium of known drug resistance mechanisms with emerging tumor profiling technologies Leukemia 33 863 883 2019 10.1038/s41375-018-0362-z 30683909 · DOI
  4. [4]Velez R Turesson I Landgren O Kristinsson SY Cuzick J Incidence of multiple myeloma in Great Britain, Sweden, and Malmö, Sweden: The impact of differences in case ascertainment on observed incidence trends BMJ Open 6 e009584 2016 10.1136/bmjopen-2015-009584 PMC4735168 26801465 · DOI
  5. [5]Chen D Zhou D Xu J Zhou R Ouyang J Chen B Prognostic value of 1q21 gain in multiple myeloma Clin Lymphoma Myeloma Leuk 19 e159 e164 2019 10.1016/j.clml.2018.12.002 30685183 · DOI
  6. [6]Bartel DP MicroRNAs: Target recognition and regulatory functions Cell 136 215 233 2009 10.1016/j.cell.2009.01.002 19167326 PMC3794896 · DOI · Paper page
  7. [7]Handa H Murakami Y Ishihara R Kimura-Masuda K Masuda Y The role and function of microRNA in the pathogenesis of multiple myeloma Cancers (Basel) 11 1378 2019 10.3390/cancers11111738 PMC6896016 31698726 · DOI
  8. [8]Adamia S Abiatari I Amin SB Fulciniti M Minvielle S Li C Moreau P Avet-Loiseau H Munshi NC Anderson KC The effects of MicroRNA deregulation on pre-RNA processing network in multiple myeloma Leukemia 34 167 179 2020 10.1038/s41375-019-0498-5 31182781 PMC6901818 · DOI
  9. [9]Xu YY Song YQ Huang ZM Zhang HB Chen M MicroRNA-26a inhibits multiple myeloma cell growth by suppressing cyclin-dependent kinase 6 expression Kaohsiung J Med Sci 35 277 283 2019 10.1002/kjm2.12057 30897301 PMC11900684 · DOI
  10. [10]Tian F Zhan Y Zhu W Li J Tang M Chen X Jiang J MicroRNA-497 inhibits multiple myeloma growth and increases susceptibility to bortezomib by targeting Bcl-2 Int J Mol Med 43 1058 1066 2019 30535471
  11. [11]Gupta N Kumar R Seth T Garg B Sati HC Sharma A Clinical significance of circulatory microRNA-203 in serum as novel potential diagnostic marker for multiple myeloma J Cancer Res Clin Oncol 145 1601 1611 2019 10.1007/s00432-019-02896-1 30891618 PMC11810419 · DOI
  12. [12]Zhang YK Wang H Leng Y Li ZL Yang YF Xiao FJ Li QF Chen XQ Wang LS Overexpression of microRNA-29b induces apoptosis of multiple myeloma cells through down regulating Mcl-1 Biochem Biophys Res Commun 414 233 239 2011 10.1016/j.bbrc.2011.09.063 21951844 · DOI
  13. [13]Jia CM Tian YY Quan LN Jiang L Liu AC miR-26b-5p suppresses proliferation and promotes apoptosis in multiple myeloma cells by targeting JAG1 Pathol Res Pract 214 1388 1394 2018 10.1016/j.prp.2018.07.025 30098829 · DOI
  14. [14]Zhang J Gong X Tian K Chen D Sun J Wang G Guo M miR-25 promotes glioma cell proliferation by targeting CDKN1C Biomed Pharmacother 71 7 14 2015 10.1016/j.biopha.2015.02.005 25960208 · DOI
  15. [15]Sanchez-Mejias A Kwon J Chew XH Siemens A Sohn HS Jing G Zhang B Yang H Tay Y A novel SOCS5/miR-18/miR-25 axis promotes tumorigenesis in liver cancer Int J Cancer 144 311 321 2019 10.1002/ijc.31857 30191950 · DOI
  16. [16]Navarro A Diaz T Tovar N Pedrosa F Tejero R Cibeira MT Magnano L Rosiñol L Monzó M Bladé J Fernández de Larrea C A serum microRNA signature associated with complete remission and progression after autologous stem-cell transplantation in patients with multiple myeloma Oncotarget 6 1874 1883 2015 10.18632/oncotarget.2761 25593199 PMC4359338 · DOI
  17. [17]Xiang T Hu AX Sun P Liu G Liu G Xiao Y Identification of four potential predicting miRNA biomarkers for multiple myeloma from published datasets PeerJ 5 e2831 2017 10.7717/peerj.2831 28168095 PMC5289111 · DOI
  18. [18]Palumbo A Avet-Loiseau H Oliva S Lokhorst HM Goldschmidt H Rosinol L Richardson P Caltagirone S Lahuerta JJ Facon T Revised international staging system for multiple myeloma: A report from international myeloma working group J Clin Oncol 33 2863 2869 2015 10.1200/JCO.2015.61.2267 26240224 PMC4846284 · DOI · Paper page
  19. [19]International Myeloma Working Group Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the international myeloma working group Br J Haematol 121 749 757 2003 10.1046/j.1365-2141.2003.04355.x 12780789 · DOI
  20. [20]Livak KJ Schmittgen TD Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method Methods 25 402 408 2001 10.1006/meth.2001.1262 11846609 · DOI · Paper page
  21. [21]Franke TF PI3K/Akt: Getting it right matters Oncogene 27 6473 6488 2008 10.1038/onc.2008.313 18955974 · DOI
  22. [22]Wang X Jiang X PTEN: A default gate-keeping tumor suppressor with a versatile tail Cell Res 18 807 816 2008 10.1038/cr.2008.83 18626510 · DOI
  23. [23]Sarbassov DD Guertin DA Ali SM Sabatini DM Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex Science 307 1098 1101 2005 10.1126/science.1106148 15718470 · DOI · Paper page
  24. [24]Razumilava N Bronk SF Smoot RL Fingas CD Werneburg NW Roberts LR Mott JL miR-25 targets TNF-related apoptosis inducing ligand (TRAIL) death receptor-4 and promotes apoptosis resistance in cholangiocarcinoma Hepatology 55 465 475 2012 10.1002/hep.24698 21953056 PMC3268937 · DOI
  25. [25]Feng S Pan W Jin Y Zheng J MiR-25 promotes ovarian cancer proliferation and motility by targeting LATS2 Tumour Biol 35 12339 12344 2014 10.1007/s13277-014-2546-0 25179841 · DOI
  26. [26]Boguslawska J Rodzik K Poplawski P Kędzierska H Rybicka B Sokół E Tański Z Piekiełko-Witkowska A TGF-beta1 targets a microRNA network that regulates cellular adhesion and migration in renal cancer Cancer Lett 412 155 169 2018 10.1016/j.canlet.2017.10.019 29079415 · DOI
  27. [27]Huo J Zhang Y Li R Wang Y Wu J Zhang D Upregulated MicroRNA-25 mediates the migration of melanoma cells by targeting DKK3 through the WNT/β-catenin pathway Int J Mol Sci 17 1124 2016 10.3390/ijms17111124 PMC5133768 27801786 · DOI
  28. [28]Ning L Zhang M Zhu Q Hao F Shen W Chen D miR-25-3p inhibition impairs tumorigenesis and invasion in gastric cancer cells in vitro and in vivo Bioengineered 11 81 90 2020 10.1080/21655979.2019.1710924 31909687 PMC6961587 · DOI
  29. [29]Liu H Ma L Wang J Overexpression of miR-25 is associated with progression and poor prognosis of cholangiocarcinoma Exp Ther Med 18 2687 2694 2019 31555370 PMC6755412
  30. [30]Chen H Pan H Qian Y Zhou W Liu X MiR-25-3p promotes the proliferation of triple negative breast cancer by targeting BTG2 Mol Cancer 17 4 2018 10.1186/s12943-017-0754-0 29310680 PMC5759260 · DOI
  31. [31]Wan W Wan W Long Y Li Q Jin X Wan G Zhang F Lv Y Zheng G Li Z Zhu Y MiR-25-3p promotes malignant phenotypes of retinoblastoma by regulating PTEN/Akt pathway Biomed Pharmacother 118 109111 2019 10.1016/j.biopha.2019.109111 31336343 · DOI
  32. [32]Peng G Yang C Liu Y Shen C miR-25-3p promotes glioma cell proliferation and migration by targeting FBXW7 and DKK3 Exp Ther Med 18 769 778 2019 31258712 PMC6566094
  33. [33]Kim YK Yu J Han TS Park SY Namkoong B Kim DH Hur K Yoo MW Lee HJ Yang HK Kim VN Functional links between clustered microRNAs: Suppression of cell-cycle inhibitors by microRNA clusters in gastric cancer Nucleic Acids Res 37 1672 1681 2009 10.1093/nar/gkp002 19153141 PMC2655672 · DOI
  34. [34]Li Y Tan W Neo TW Aung MO Wasser S Lim SG Tan TM Role of the miR-106b-25 microRNA cluster in hepatocellular carcinoma Cancer Sci 100 1234 1242 2009 10.1111/j.1349-7006.2009.01164.x 19486339 · DOI
  35. [35]Poliseno L Salmena L Riccardi L Fornari A Song MS Hobbs RM Sportoletti P Varmeh S Egia A Fedele G Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation Sci Signal 3 ra29 2010 10.1126/scisignal.2000594 20388916 PMC2982149 · DOI · Paper page
  36. [36]Carnero A Blanco-Aparicio C Renner O Link W Leal JF The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications Curr Cancer Drug Targets 8 187 198 2008 10.2174/156800908784293659 18473732 · DOI
  37. [37]Jiang Y Chang H Chen G Effects of microRNA-20a on the proliferation, migration and apoptosis of multiple myeloma via the PTEN/PI3K/AKT signaling pathway Oncol Lett 15 10001 10007 2018 29963125 PMC6020174
  38. [38]Qu L Gao Y Sun H Wang H Liu X Sun D Role of PTEN-Akt-CREB signaling pathway in nervous system impairment of rats with chronic arsenite exposure Biol Trace Elem Res 170 366 372 2016 10.1007/s12011-015-0478-1 26296331 · DOI
  39. [39]Aziz AUR Farid S Qin K Wang H Liu B PIM kinases and their relevance to the PI3K/AKT/mTOR pathway in the regulation of ovarian cancer Biomolecules 8 7 2018 10.3390/biom8010007 PMC5871976 29401696 · DOI
  40. [40]Waniczek D Śnietura M Lorenc Z Nowakowska-Zajdel E Muc-Wierzgon M Assessment of PI3K/AKT/PTEN signaling pathway activity in colorectal cancer using quantum dot-conjugated antibodies Oncol Lett 15 1236 1240 2018 29422975 PMC5772923
  41. [41]Yu T Li L Liu W Ya B Cheng H Xin Q Silencing of NADPH oxidase 4 attenuates hypoxia resistance in neuroblastoma cells SH-SY5Y by inhibiting PI3K/Akt-dependent glycolysis Oncol Res 27 525 532 2019 10.3727/096504018X15179668157803 29426376 PMC7848326 · DOI
  42. [42]Xu H Li J Zhou ZG NEAT1 promotes cell proliferation in multiple myeloma by activating PI3K/AKT pathway Eur Rev Med Pharmacol Sci 22 6403 6411 2018 30338809

Cited by

Sorted by citations

Metadata

Authors
Zi, Y., Zhang, Y., Wu, Y., Zhang, L., Yang, R., & Huang, Y.
Affiliations
  • First Affiliated Hospital of Xinxiang Medical University (CN)
  • Central Laboratory, The First Affiliated Hospital of Xinxiang Medical University, Weihui, Henan 453100, P.R. China
Corresponding author
Zi, Youmei
ORCID
Venue
International Journal of Molecular Medicine
Publisher
Spandidos Publications
Published
2020-12-31
Volume
47
Issue
3
ISSN
  • 1107-3756 (ISSN-L)
  • 1791-244X
DOI
10.3892/ijmm.2020.4841
PMC
PMC7834966
OpenAlex
W3116250464
Cited by
40
References
0
Citations by year
2025: 10 · 2024: 14 · 2023: 6 · 2022: 8 · 2021: 2
FWCI
2.53
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • International Journal of Molecular Medicine (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
  • Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
Keywords
miR-25-3p, multiple myeloma, PTEN, PI3K/Akt signaling, cell proliferation, apoptosis, prognostic factors, therapeutic target, microRNA downregulation, tumor suppressor
MeSH terms
Aged, Female, Humans, Male, Middle Aged, Multiple Myeloma, RNA, Neoplasm, Signal Transduction, Down-Regulation, Gene Expression Regulation, Neoplastic, Apoptosis, Phosphatidylinositol 3-Kinases, MicroRNAs, Cell Line, Tumor, Proto-Oncogene Proteins c-akt, PTEN Phosphohydrolase

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review